降糖药物与心力衰竭住院:超50万患者年的系统评价与相加效应网络Meta分析
结果显示SGLT2抑制剂单用或联合DPP4抑制剂降低HHF风险,噻唑烷二酮单用或联合DPP4抑制剂增加HHF风险,而HbA1c每降低1%可额外降低HHF风险31.3%。
要点
- SGLT2抑制剂单用或联合DPP4抑制剂可降低心力衰竭住院风险。
- 噻唑烷二酮单用或联合DPP4抑制剂增加心力衰竭住院风险。
- 无论何种降糖治疗,HbA1c降低1%可降低HHF风险31.3%。
核心结论
- SGLT2抑制剂单用或联合DPP4抑制剂降低HHF风险,噻唑烷二酮单用或联合增加HHF风险,降糖本身提供降低HHF的相加效应。
主要发现
- 二甲双胍(P=0.55)、磺脲类(P=0.51)、GLP-1受体激动剂(P=0.16)和DPP4抑制剂(P=0.54)对HHF风险为中性。
- SGLT2抑制剂降低HHF风险(HR 0.68,95%CI 0.60-0.76,P<0.0001),SGLT2抑制剂联合DPP4抑制剂亦降低(HR 0.70,95%CI 0.60-0.81,P<0.0001)。
- 噻唑烷二酮单药增加HHF风险(HR 1.45,95%CI 1.18-1.78,P=0.0004),联合DPP4抑制剂亦增加(HR 1.49,95%CI 1.18-1.88,P=0.0008)。
- 无论何种治疗,HbA1c降低1%使HHF风险降低31.3%(95%CI 9-48,P=0.009)。
关键数值与推荐
- SGLT2抑制剂单用HR 0.68(95%CI 0.60-0.76,P<0.0001),SGLT2抑制剂+DPP4抑制剂HR 0.70(95%CI 0.60-0.81,P<0.0001)。
- 噻唑烷二酮单用HR 1.45(95%CI 1.18-1.78,P=0.0004),噻唑烷二酮+DPP4抑制剂HR 1.49(95%CI 1.18-1.88,P=0.0008)。
- HbA1c降低1%对应HHF风险降低31.3%(95%CI 9-48,P=0.009)。
临床怎么用
- 对于2型糖尿病合并心力衰竭高风险患者,优先考虑SGLT2抑制剂单用或联合DPP4抑制剂以降低HHF风险。
- 避免使用噻唑烷二酮单药或联合DPP4抑制剂,尤其在心衰高风险人群中。
- 在制定降糖方案时,兼顾HbA1c达标以获取降低HHF的额外获益。
局限性
- 缺乏数据验证临床可用的药物组合,也无法区分同一治疗类别内不同药物的效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium glucose co-transporter 2 inhibitors (SGLT2is) prevent hospitalization resulting from heart failure (HHF). However, patients with type 2 diabetes mellitus use multiple antihyperglycemic drugs to achieve glycosylated hemoglobin (HbA1c) targets. In these drug combinations, the risk of HHF is unpredictable and so is the parallel effect of glucose-lowering. PURPOSE: To examine the impact of antihyperglycemic drugs and their association on HHF. DATA SOURCES: Forty randomized controlled trials (RCTs) reporting HHF. STUDY SELECTION: Published RCTs were the data source. DATA EXTRACTION: Incidence rates of HHF. DATA SYNTHESIS: Random additive-effects network meta-analysis showed that metformin (P = 0.55), sulfonylureas (P = 0.51), glucagon-like peptide-1 receptor-agonist (P = 0.16), and dipeptidyl peptidase 4 inhibitors (DPP4is; P = 0.54) were neutral on the risk of HHF. SGLT2is and SGLT2is + DPP4is reduced the risk of HHF with a hazard ratio (HR) of 0.68 (95% CI, 0.60-0.76; P < 0.0001) and 0.70 (95% CI, 0.60-0.81; P < 0.0001), respectively. Increased risk of HHF was associated with thiazolidinediones (TZDs) as monotherapy or in combination with DPP4is (HR: 1.45; 95% CI, 1.18-1.78; P = 0.0004) and 1.49 (95% CI, 1.18-1.88; P = 0.0008), respectively. Regardless of the therapy, a 1% reduction in HbA1c reduced the risk of HHF by 31.3% (95% CI, 9-48; P = 0.009). LIMITATIONS: There are no data to verify drug combinations available for clinical use and to discriminate the effect of drugs within each of the therapeutic classes. CONCLUSIONS: The risk of HHF is reduced by SGLT2is as monotherapy or in combination with DPP4is and increased by TZDs as monotherapy or in combination. Glucose-lowering provides an additive effect of reducing HHF.
引用
- Cintra RM, Nogueira AC, Bonilha I, et al. Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years. J Clin Endocrinol Metab. 2021. PMID: 34125217. doi:10.1210/clinem/dgab428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。